Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial.

• Three small trials suggest that intravenous immunoglobulin can affect biomarkers and symptoms of mild-to-moderate Alzheimer's disease. We tested the safety, effective dose, and infusion interval of intravenous immunoglobulin in such patients.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Neurosciences (hsv//eng)

Nyckelord

Aged

Aged

80 and over

Alzheimer Disease

diagnosis

drug therapy

immunology

Amyloid beta-Peptides

blood

Area Under Curve

Dose-Response Relationship

Drug

Double-Blind Method

Female

Humans

Immunoglobulins

Intravenous

administration & dosage

adverse effects

blood

Male

Middle Aged

Placebos

Severity of Illness Index

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)